Skip to main content
"By creating we think, by living we learn" Patrick Geddes
Main University menu
 

Templates Top-Level Menu

Image of Prof Helen Colhoun

Professor Helen Colhoun

Chair of Public Health and Honorary Consultant in Public Health, NHS Fife

Address:

Biomedical Research Institute
Level 7,
Ninewells Hospital and Medical School

Telephone: +44 (0) 1382 660111 ext. 20103

h.colhoun@chs.dundee.ac.uk


  • Research

    • Helen Colhoun joined the University of Dundee in September 2007 having previously held professorial posts at the University College London and University College Dublin. Her major research interest is the epidemiology, including genetic epidemiology, of diabetes and its complications. Her current research programme includes

    • Large-scale genetic epidemiology studies. These include studies of genetic determinants of diabetic nephropathy in both type 1 diabetes (in the Eurodiab Family Study cohort) and type 2 diabetes (in the Wellcome Trust Type 2 Diabetes Case-Control Collection in Tayside), genome-wide association studies of intermediate phenotypes relevant to cardiovascular disease in diabetes and of statin response in the (Collaborative Atorvastatin Diabetes Study CARDS of which she was Co-PI).
    • Studies that harness the power of Scottish data-linkage systems and clinical databases to study the epidemiology of diabetes complications and to conduct pharmacovigilance studies relevant to drugs used by patients with diabetes. This is part of the recently funded £4.7 million Scottish Health Informatics Programme from Wellcome Trust.
    • discovery and validation studies for biomarkers of diabetic complications
    • developing new clinical trials in diabetes patients.
  • Publications

    • Articles/research papers in last 3 years.

    1. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010 May;53(5):809-20
    2. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009 Sep;52(9):1755-65.
    3. Scottish Diabetes Survey Monitoring Group. Scottish Diabetes Survey 2009. NHS Scotland.
    4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS investigators. Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients with Diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases. 2009 Nov;54(5):810-9.
    5. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, Demicco DA, Durrington PN. Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009 Mar;55(3):473-80.
    6. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2009 Feb;52(2):218-25.
    7. Scottish Diabetes Survey Monitoring Group. Scottish Diabetes Survey 2008. NHS Scotland.
    8. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA, de Vries CS. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia. 2008 Jun 26.
    9. Colhoun HM, Slaney J, Rubens MB, Fuller JH, Sheiham A, Curtis MA. Antibodies to Periodontal Pathogens and Coronary Artery Calcification in Type 1 Diabetic and Non-Diabetic Subjects. J Periodontol Res 2008; 43(1):103-10.
    10. Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, DeMicco DA, Auster S, Fuller JH, on behalf of the CARDS Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res. 2008;5:177-183.
    11. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117–25
    12. Colhoun HM. Lipid goals in Metabolic Syndromes and Diabetes. Current Ath Reports. 2007. 2007 Oct;9(4):286-95.
    13. Hitman GA, Colhoun HM, Newman C, et al. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS) . Diabetic Med 2007 Dec;24(12):1313-21.
      Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Charlton-Menys V, Fuller JH on behalf of the CARDS Investigators. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Diabetologia 2007; 50(4):733-40.